- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06373289
Mål oksygenområder hos spedbarn med pulmonal hypertensjon (PHOX)
Mål oksygenmetningsområder hos spedbarn med bronkopulmonal dysplasi assosiert pulmonal hypertensjon
Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.
Studieoversikt
Status
Detaljert beskrivelse
Infants born between 22.0 to 31.6 weeks' gestational age with bronchopulmonary dysplasia associated pulmonary hypertension, are receiving supplemental oxygen, and have mature retinas will be randomized to SpO2 targets of either (1) 92-95% (control) or (2) 95-98% (intervention).
Using a cross over design with a 1:1 parallel allocation of infants randomized using a stratified permuted block design. Following 1week of exposure A, infants will cross over to exposure B for 1 week with a 1-week washout period. Bedside providers will follow pre-specified algorithms to maintain oxygen targets during the randomization period. Reports of oxygen saturation performance will also be provided to bedside providers through oxygen saturation histograms.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Samuel Gentle, MD
- Telefonnummer: 205-541-2247
- E-post: samjgentle@gmail.com
Studer Kontakt Backup
- Navn: Colm Travers
- E-post: samuel.gentle@yale.edu
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- Rekruttering
- The University of Alabama at Birmingham
-
Ta kontakt med:
- Colm Travers
- Telefonnummer: 205-934-4011
- E-post: cptravers@uabmc.edu
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Yale New Haven Hospital
-
Ta kontakt med:
- Samuel Gentle
- Telefonnummer: 205-541-2247
- E-post: samuel.gentle@yale.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Between 22w 0/7d and 31w 6/7d gestation at birth
- Diagnosed with echocardiographic pulmonary hypertension (1) >20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index >1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
- Receiving supplemental oxygen
- Have mature retinas
Exclusion Criteria:
- Major congenital anomalies
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Oxygen saturation target 92-95%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed to a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the lower oxygen saturation target. |
|
Aktiv komparator: Oxygen saturation target 95-98%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 95-98% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the higher oxygen saturation target. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intermittent hypoxemia event duration
Tidsramme: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
The average duration of time (in seconds) an infant's oxygen saturation decrease below 80%. |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Echocardiographic shunting
Tidsramme: through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
>20% flow of blood across the PDA from the pulmonary to arterial circulation |
through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic interventricular septal flattening
Tidsramme: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
End-systolic flattening of the interventricular septum (eccentricity index >1.3) |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic tricuspid regurgitation
Tidsramme: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Right ventricular pressure estimates |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Intermittent hypoxemia frequency
Tidsramme: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Number of daily events during which an infant's oxygen saturation decreases below 80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Cumulative hypoxemia
Tidsramme: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Daily duration during which an infant's oxygen saturation is <80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Brain natriuretic peptide
Tidsramme: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
A polypeptide released from the cardiac ventricles indicative of right heart strain |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Samuel Gentle, Yale University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Sykdommer i luftveiene
- Lungesykdommer
- Spedbarn, premature, sykdommer
- Spedbarn, nyfødte, sykdommer
- Hypertensjon
- Lungeskade
- Ventilator-indusert lungeskade
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Hypertensjon, lunge
- Bronkopulmonal dysplasi
Andre studie-ID-numre
- 000539476
- 1K23HD113837-01A1 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .